REMS requires patients to administer Spravato at a clinic in the presence of a physician. “We probably know more about the adverse event profile of intranasal ketamine than, I may argue ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

or REMS, program. People taking Spravato can only do so at clinics or medical offices certified to distribute it, and only under direct medical supervision. Still, Spravato’s expansion into a ...

Treatment with esketamine, Spravato, often results in effective and faster improvement of depression. We are a REMS certified Spravato Treatment Center. Have you lost hope for improving your ...

Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response to at least two oral antidepressants. It is available only through a restricted REMS program.

There’s also the chance it could be misused. Because of this, Spravato is only available at certified treatment centers where patients are closely monitored. You won’t be able to pick it up at ...

TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...